Orexigen Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.04.18	Epicor Honored as Technology Partner of the Year by Automotive Distribution Network (PR Newswire)
24.04.18	XYZprinting Presents New Ultrafast Stereolithography 3D Printer Powered by Nexa3D at Rapid + TCT 2018 (PR Newswire)
23.04.18	Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company (PR Newswire)
13.03.18	ANTH Fails To Produce RESULT, OREX Files Chapter 11 Bankruptcy, RXII On Watch (RTTNews)
12.03.18	Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code (PR Newswire)
02.03.18	TENX Heartened, AXGN Sees 40% Revenue Growth, Mark Your Calendar For REPH (RTTNews)
16.01.18	Kairoi Health Partners with athenahealth to Deliver Cloud-Based Clinic Schedule Optimization Solution (PR Newswire)
13.11.17	Orexigen Therapeutics Announces Third Quarter 2017 Financial Results (PR Newswire)
13.11.17	Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin America (PR Newswire)
31.10.17	Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13, 2017 (PR Newswire)
13.10.17	Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030 (PR Newswire)
13.10.17	Orexigen Therapeutics to Provide Business Update at the 2017 BIO Investor Forum (PR Newswire)
26.09.17	Orexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave® (PR Newswire)
05.09.17	TeleTech Hiring 12,000 New Associates Across 26 Centers in the US (PR Newswire)
24.08.17	As Harvey Makes His Way to the Texas Coast Farmers Insurance® Gets Ready to Help (PR Newswire)
08.08.17	Orexigen Therapeutics Announces Second Quarter 2017 Financial Results (PR Newswire)
07.08.17	Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria (PR Newswire)
26.07.17	Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt (PR Newswire)
25.07.17	Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017 (PR Newswire)
21.07.17	Gainers & Losers Of July 20: SRPT, AKCA, AGRX, INO, IRWD... (RTTNews)
20.07.17	Gainers & Losers Of July 19: AEZS, VRTX, AGRX, PTI, INO... (RTTNews)
10.07.17	Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of... (PR Newswire)
31.05.17	How These Drug Makers Stocks are Faring? -- Depomed, Pernix Therapeutics, United Therapeutics, and Orexigen Therapeutics (PR Newswire)
16.05.17	Orexigen Announces Activities at European Congress on Obesity 2017 (PR Newswire)
09.05.17	Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 (PR Newswire)
02.05.17	Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries (PR Newswire)
26.04.17	Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017 (PR Newswire)
25.04.17	Research Reports Initiation on Drug Makers Stocks -- Depomed, Pernix Therapeutics, Orexigen Therapeutics, and United Therapeutics (PR Newswire)
25.04.17	Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada (PR Newswire)
05.04.17	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors (PR Newswire)
04.04.17	Gainers & Losers Of The Day: CYCC, NVCR, STDY, ACOR, OREX... (RTTNews)
28.03.17	Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 (PR Newswire)
28.03.17	Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy (PR Newswire)
20.03.17	How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma (PR Newswire)
08.03.17	Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017 (PR Newswire)
07.02.17	Orexigen Therapeutics to Speak at Upcoming Investor Conferences (PR Newswire)
31.01.17	Drug Makers Stocks on Investors' Radar -- Depomed, United Therapeutics, DURECT, and Orexigen Therapeutics (PR Newswire)
25.01.17	Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmacéuticos Rovi, S.A. (PR Newswire)
06.01.17	Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release tablets) Real-World Study Results in "Obesity" (PR Newswire)
05.01.17	Orexigen Therapeutics Highlights Key Business Priorities for 2017 (PR Newswire)
04.01.17	Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to Educate Consumers on the Role of the Brain in Weight Loss (PR Newswire)
08.12.16	Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Consilient Health Ltd. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in the UK and Ireland (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Kuehne+Nagel Int	202.80	0.65 %	K V
Swiss Life Hldg	759.40	0.53 %	K V
Lonza Grp	606.40	0.43 %	K V
Zurich Insur Gr	565.80	0.43 %	K V
Part Grp Hldg	1’391.50	0.40 %	K V
ABB	49.60	-0.16 %	K V
Swisscom	526.00	-0.19 %	K V
Geberit	507.00	-0.20 %	K V
Roche Hldg G	287.50	-0.52 %	K V
Givaudan	3’819.00	-0.81 %	K V

Nachrichten zu Orexigen Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten